Bo Hansen - Swedish Orphan Insider

BIOVF -- USA Stock  

USD 21.80  0.000001  0.00%

Chairman of the Board

Dr. Bo Jesper Hansen M.D. Ph.D. no longer serves as Chairman of the Board of Directors of Swedish Orphan Biovitrum AB effective as of May 24 2016. He has held this position since April 27 2010. He was Member of the Company Board since 2010. He has also served as Member of the Company Nomination Committee and Scientific Committee and Chairman of the Compensation and Benefits Committee. During the course of his career Mr. Hansen has held various positions within Swedish Orphan International AB from 1993 most recently as Chief Executive Officer . He is Founder of Scandinavian Medical Research and has served as Medical Advisor to Synthelabo Pfizer and Yamanouchi. He serves as Member of the Board of Directors of GenSpera Inc. Newron Pharmaceuticals SpA Orphazyme ApS CMC AB Azanta AS Karolinska Development AB and Ablynx NV. He holds a Medical Doctor degree with a Doctor of Philosophy degree from Koebenhavns Universitet.
Age: 57  Chairman Since 2010  Ph.D    
46 86 97 20 00  http://www.sobi.com

Management Efficiency

The company has return on total asset (ROA) of 11.67 % which means that it generated profit of $11.67 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 22.83 % meaning that it generated $22.83 on every $100 dollars invested by stockholders.
The company has accumulated 685.86 K in total debt. Swedish Orphan Biovitrum AB has Current Ratio of 1.85 which is within standard range for the sector.

Similar Executives

Entity Summary

Swedish Orphan Biovitrum AB , an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetic and lysosomal diseases. Swedish Orphan Biovitrum AB is headquartered in Solna, Sweden. Swedish Orphan is traded on OTC Market in USA.Swedish Orphan Biovitrum AB (BIOVF) is traded on OTC Market in USA. It is located in Tomtebodav?gen 23A and employs 816 people.

Swedish Orphan Biovi Leadership Team

Hans Wigzell, Director, Ph.D
Lennart Johansson, Director, MBA
Annette Clancy, Director
Trista Morrison, President
Kirsti Gjellan, President
Jorgen Winroth, VP
Milan Zdravkovic, President, Ph.D
Hans Schikan, Director
Dennis Pedersen, President
Helena Saxon, Director, MBA
Anders Edvell, Executive, MBA
Geoffrey McDonough, CEO, Ph.D
Lars Dreioee, President, MBA
Alan Raffensperger, COO
Fredrik Berg, Executive
BoGunnar Rosenbrand, Director
Adine Axen, Director
Birgitte Volck, President
MatsOlof Wallin, President
Stefan Fraenkel, President, MBA
Hakan Bjorklund, Chairman, Ph.D
Cecilia Forberg, President
Stephen James, President, Ph.D
Bo Hansen, Chairman, Ph.D
Armin Reininger, President, Ph.D
Catarina Larsson, Director
David Allsop, Director
Elisabeth Svanberg, Director
Wills HughesWilson, President
Guido Oelkers, CEO
Jeffrey Jonas, Director, Ph.D
Matthew Gantz, Director, MBA
Theresa Heggie, Director

Stock Performance Indicators

Current Sentiment - BIOVF

Swedish Orphan Biovi Investor Sentiment
Macroaxis portfolio users are unresponsive in their opinion about investing in Swedish Orphan Biovitrum AB. What is your outlook on investing in Swedish Orphan Biovitrum AB? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip

Pair Correlation

Equities Pair Trading Analysis
Correlation analysis and pair trading evaluation for Swedish Orphan and U S Bancorp. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try Piotroski F Score module to get piotroski f score based on binary analysis strategy of nine different fundamentals.